U.S. Markets closed
  • S&P Futures

    +33.50 (+0.92%)
  • Dow Futures

    +260.00 (+0.88%)
  • Nasdaq Futures

    +109.50 (+0.89%)
  • Russell 2000 Futures

    +23.00 (+1.26%)
  • Crude Oil

    -0.36 (-0.79%)
  • Gold

    +6.40 (+0.36%)
  • Silver

    +0.35 (+1.56%)

    +0.0027 (+0.2273%)
  • 10-Yr Bond

    +0.0020 (+0.24%)
  • Vix

    -0.27 (-1.30%)

    +0.0027 (+0.2004%)

    +0.1060 (+0.1016%)

    +44.65 (+0.23%)
  • CMC Crypto 200

    +19.32 (+5.30%)
  • FTSE 100

    -101.39 (-1.59%)
  • Nikkei 225

    +390.84 (+1.48%)

BMRN, CACC SHAREHOLDER ALERT: Hagens Berman, National Trial Attorneys, Updates BMRN, CACC Investors on Securities Class Actions, Encourages Investors with Losses to Contact Firm

·4 min read

SAN FRANCISCO, CA / ACCESSWIRE / October 20, 2020 / Hagens Berman updates investors in the following publicly-traded companies and urges investors who have suffered significant losses to contact the firm. Further details about the cases can be found at the links provided.

BMRN Investors Click Here.

CACC Investors Click Here.

BioMarin Pharmaceutical (NASDAQ:BMRN) Securities Class Action:

Class Period: Feb. 28, 2020 - Aug. 18, 2020
Lead Plaintiff Deadline: Nov. 24, 2020
Visit: www.hbsslaw.com/investor-fraud/BMRN
Contact An Attorney Now: BMRN@hbsslaw.com

The complaint alleges that Defendants' statements misrepresented and concealed material information about BioMarin's valoctocogene roxaparvovec product candidate, potentially the first gene therapy approved by the U.S. FDA for hemophilia in the U.S.

Specifically, throughout the Class Period, Defendants misstated or omitted to disclose that (1) differences between the phase 1/2 and phase 3 study of valoctocogene roxaparvovec limited the reliability of the phase 1/2 study to support valoctocogene roxaparvovec's durability of effect, and (2) as a result, it was foreseeable that the FDA would not approve BioMarin's Biologics License Application ("BLA") for valoctocogene roxaparvovec without additional data.

Investors allegedly began to learn the truth on Aug. 19, 2020, when BioMarin announced it received the FDA's complete response letter ("CRL") to the BLA indicating the FDA recommended the company submit additional data upon completion of the phase 3 study since the difference between the phase 1/2 and phase 3 studies limited the FDA's ability to rely on the phase 1/2 study to support the durability of effect.

Analysts at Guggenheim were shocked by the Company's disclosure, noting "[t]his news came as a negative surprise to us in light of mgt commentary and other launch-related prep (by BMRN and other payers) and pushes out a potential Roctavian approval until ~2022."

This news drove the price of BioMarin shares down over 35% that day.

"We're focused on investors' losses and proving Defendants misled investors about the phase 1/2 reliability for the BLA," said Reed Kathrein, the Hagens Berman partner leading the investigation.

If you are a BioMarin investor or may assist the firm's investigation, click here to discuss your legal rights with Hagens Berman.

Credit Acceptance Corp. (NASDAQ:CACC) Securities Fraud Class Action:

Class Period: Nov. 1, 2019 - Aug. 28, 2020
Lead Plaintiff Deadline: Dec. 1, 2020
Visit: www.hbsslaw.com/investor-fraud/CACC
Contact An Attorney Now: CACC@hbsslaw.com

The Complaint alleges that, throughout the Class Period, Defendants misrepresented and concealed that: (1) CACC topped off packaged and securitized pools of loans with higher-risk loans; (2) the company made high-interest subprime auto loans it knew borrowers could not repay; (3) borrowers were subject to hidden finance charges, resulting in loans exceeding the state law mandated usury rate ceiling; (4) the company engaged in illegal debt collection practices; and, (5) that the company was likely to face regulatory scrutiny and possible penalties.

Investors allegedly began to learn the ugly truth on Aug. 28, 2020, when the Massachusetts Attorney General sued Credit Acceptance. The AG alleged that since 2013 the company topped off packaged and securitized loan pools with higher-risk loans despite telling investors otherwise. The AG also alleged Credit Acceptance's business model is predicated on making loans to borrowers who are unlikely to repay them then engaging in abusive or unlawful debt collection practices to make money.

This news sent the price of Credit Acceptance shares crashing $85.36 lower, or over 18%, during the next two trading days.

"We're focused on investors' losses and proving Credit Acceptance concealed its deceptive and illegal lending and collection practices," said Reed Kathrein, the Hagens Berman partner leading the investigation.

If you are a Credit Acceptance investor, click here to discuss your legal rights with Hagens Berman.

Whistleblowers: Persons with non-public information regarding BioMarin and/or Credit Acceptance should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email BMRN@hbsslaw.com and/or CACC@hbsslaw.com.

# # #

About Hagens Berman

Hagens Berman is a national law firm with nine offices in eight cities around the country and eighty attorneys. The firm represents investors, whistleblowers, workers and consumers in complex litigation. More about the firm and its successes is located at hbsslaw.com. For the latest news visit our newsroom or follow us on Twitter at @classactionlaw.


Reed Kathrein, 844-916-0895

SOURCE: Hagens Berman Sobol Shapiro LLP

View source version on accesswire.com: